{"id":60572,"date":"2026-03-23T15:43:13","date_gmt":"2026-03-23T07:43:13","guid":{"rendered":"https:\/\/flcube.com\/?p=60572"},"modified":"2026-03-23T15:43:14","modified_gmt":"2026-03-23T07:43:14","slug":"gsk-wins-fda-approval-for-lynavoy-first-us-treatment-for-pbc-cholestatic-pruritus-as-alfasigma-acquisition-nears-close","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60572","title":{"rendered":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) announced that the <strong>US Food and Drug Administration (FDA)<\/strong> has approved <strong>Lynavoy (linerixibat)<\/strong> for the treatment of <strong>cholestatic pruritus in adult patients with primary biliary cholangitis (PBC)<\/strong> \u2013 marking the <strong>first FDA\u2011approved medicine<\/strong> for this indication and validating the <strong>ileal bile acid transporter (IBAT) inhibition<\/strong> mechanism just weeks before the asset&#8217;s <strong>divestiture to Alfasigma S.p.A.<\/strong> closes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>US Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Lynavoy (linerixibat)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>GlaxoSmithKline plc (NYSE: GSK)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td><strong>Ileal bile acid transporter (IBAT) inhibitor<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cholestatic pruritus in adult PBC patients<\/td><\/tr><tr><td><strong>Global First<\/strong><\/td><td><strong>First medicine approved in the US<\/strong> for PBC cholestatic pruritus<\/td><\/tr><tr><td><strong>Divestiture Status<\/strong><\/td><td>Worldwide rights transferring to <strong>Alfasigma S.p.A.<\/strong> (announced March 9, 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-glisten-phase-3\">Clinical Evidence \u2013 GLISTEN Phase 3<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met<\/td><td>Regulatory approval basis<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Met<\/td><td>Comprehensive efficacy validation<\/td><\/tr><tr><td><strong>Onset of Action<\/strong><\/td><td><strong>Week 2<\/strong><\/td><td>Rapid itch relief \u2013 critical for patient quality of life<\/td><\/tr><tr><td><strong>Sustained Efficacy<\/strong><\/td><td><strong>24 weeks<\/strong><\/td><td>Durable benefit supports chronic use<\/td><\/tr><tr><td><strong>Pruritus Improvement<\/strong><\/td><td>Significant vs. placebo<\/td><td>Addresses primary PBC symptom (often debilitating)<\/td><\/tr><tr><td><strong>Sleep Interference<\/strong><\/td><td>Significant improvement vs. placebo<\/td><td>Secondary quality\u2011of\u2011life benefit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design:<\/strong> Global GLISTEN Phase 3; placebo\u2011controlled<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> PBC patients with cholestatic pruritus (chronic itch driven by bile acid accumulation)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-context-alfasigma-acquisition\">Transaction Context \u2013 Alfasigma Acquisition<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>GSK Position<\/th><th>Alfasigma Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Timing<\/strong><\/td><td>Announced <strong>March 9, 2026<\/strong><\/td><td>Acquisition pending close<\/td><\/tr><tr><td><strong>Asset Transfer<\/strong><\/td><td>Worldwide exclusive rights to linerixibat<\/td><td>Full development, manufacturing, commercialization ownership<\/td><\/tr><tr><td><strong>FDA Approval Impact<\/strong><\/td><td>De\u2011risks asset value; validates clinical data package<\/td><td>Acquirer gains <strong>FDA\u2011approved, first\u2011in\u2011class asset<\/strong> vs. development\u2011stage compound<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>GSK portfolio prioritization (oncology, infectious disease, HIV)<\/td><td>Alfasigma expands gastroenterology\/hepatology franchise; rare disease\/orphan positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PBC Market Dynamics:<\/strong> Primary biliary cholangitis affects <strong>~100,000 US patients<\/strong>; cholestatic pruritus occurs in <strong>60\u201170%<\/strong> of cases and is frequently treatment\u2011resistant; existing off\u2011label therapies (cholestyramine, rifampin, naltrexone) have limited efficacy and poor tolerability \u2013 <strong>US$300\u2011500 million<\/strong> addressable market for targeted therapy.<\/li>\n\n\n\n<li><strong>Lynavoy Mechanism Differentiation:<\/strong> IBAT inhibition reduces <strong>ileal bile acid reabsorption<\/strong> \u2192 decreased systemic bile acid load \u2192 reduced pruritus signaling; &#8220;multiple drivers of chronic itch&#8221; positioning suggests broader efficacy vs. single\u2011target approaches; oral administration (vs. biologics) supports primary care prescribing.<\/li>\n\n\n\n<li><strong>Alfasigma Commercial Trajectory:<\/strong> Acquisition of <strong>FDA\u2011approved first\u2011in\u2011class asset<\/strong> vs. typical development\u2011stage deal transforms Alfasigma&#8217;s US market entry; immediate revenue recognition (Q2\u2011Q3 2026 launch) vs. 3\u20114 year development timeline; European EMA submission anticipated H2 2026 with approval 2027\u20112028.<\/li>\n\n\n\n<li><strong>GSK Portfolio Optimization:<\/strong> Linerixibat divestiture consistent with <strong>CEO Emma Walmsley&#8217;s strategy<\/strong> to focus on oncology (Trodelvy, Jemperli), infectious disease (vaccines, antibiotics), and HIV; rare disease hepatology non\u2011core; proceeds (undisclosed, estimated <strong>US$200\u2011400 million<\/strong>) reinvested in priority therapeutic areas.<\/li>\n\n\n\n<li><strong>Pricing &amp; Access Considerations:<\/strong> Orphan\/rare disease positioning supports <strong>premium pricing<\/strong> (estimated US$30,000\u201150,000 annually); limited PBC patient population may qualify for <strong>FDA orphan drug exclusivity<\/strong>; payer management focused on prior authorization for documented cholestatic pruritus vs. asymptomatic PBC.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Alfasigma acquisition closing timelines, commercial launch expectations, and market penetration projections for Lynavoy. Actual results may differ due to transaction completion conditions, reimbursement negotiations, and competitive dynamics in the PBC therapeutics landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[278,15],"class_list":["post-60572","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-glaxosmithkline","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset&#039;s divestiture to Alfasigma S.p.A. closes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60572\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset&#039;s divestiture to Alfasigma S.p.A. closes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60572\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T07:43:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T07:43:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close\",\"datePublished\":\"2026-03-23T07:43:13+00:00\",\"dateModified\":\"2026-03-23T07:43:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572\"},\"wordCount\":538,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GlaxoSmithKline\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60572#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60572\",\"name\":\"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-23T07:43:13+00:00\",\"dateModified\":\"2026-03-23T07:43:14+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset's divestiture to Alfasigma S.p.A. closes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60572\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60572#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset's divestiture to Alfasigma S.p.A. closes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60572","og_locale":"en_US","og_type":"article","og_title":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close","og_description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset's divestiture to Alfasigma S.p.A. closes.","og_url":"https:\/\/flcube.com\/?p=60572","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-23T07:43:13+00:00","article_modified_time":"2026-03-23T07:43:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60572#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60572"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close","datePublished":"2026-03-23T07:43:13+00:00","dateModified":"2026-03-23T07:43:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60572"},"wordCount":538,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GlaxoSmithKline","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60572#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60572","url":"https:\/\/flcube.com\/?p=60572","name":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-23T07:43:13+00:00","dateModified":"2026-03-23T07:43:14+00:00","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC) \u2013 marking the first FDA\u2011approved medicine for this indication and validating the ileal bile acid transporter (IBAT) inhibition mechanism just weeks before the asset's divestiture to Alfasigma S.p.A. closes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60572#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60572"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60572#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Wins FDA Approval for Lynavoy \u2013 First US Treatment for PBC Cholestatic Pruritus as Alfasigma Acquisition Nears Close"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60572"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60572\/revisions"}],"predecessor-version":[{"id":60574,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60572\/revisions\/60574"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}